Clinical Trials Logo

Clinical Trial Summary

The current study will investigate whether add-on dextromethorphan (DM) and memantine (MM) is able to improve the treatment outcomes for ATSUD, and be associated with improvement in inflammatory markers, neurotrophic factors and neuropsychological tests.


Clinical Trial Description

In current study, we will conduct a randomized double-blind placebo-controlled study. We will recruit 100-120 patients with ATSUD in three years and allocate them to add-on low dose dextromethorphan and memantine (DM 30mg/day+MM 5mg/day) or placebo group in a 1: 1 ratio (patients will also undergo usual psychosocial interventions). We will follow up the participants for 12 weeks and measure the treatment responses, urine drug tests, craving scales and side effects to evaluate the therapeutic effects of add-on DM+MM. Neuropsychological assessments and tests for inflammatory parameters and neurotrophic factors will also be measured during 12-weeks follow up. The study results will show that whether add-on DM+MM is able to improve the treatment outcomes for ATSUD, and be associated with improvement in inflammatory markers, neurotrophic factors and neuropsychological tests. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03729128
Study type Interventional
Source National Cheng-Kung University Hospital
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 24, 2018
Completion date August 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT05274828 - Deep Transcranial Magnetic Stimulation for Stimulants Use Disorder N/A